Last reviewed · How we verify
NCT06813027: EVVitiCTC
Use of Allogeneic Extracellular Secretomes (EV)Derived From Umbilical Cord Mesenchymal Stromal Cells: a Phase I Open-label Safety Trial.
Phase 1 trial testing EV in Vitiligo in 13 participants. Participants enrolled and being followed up; not accepting new ones.
30 January 2026
Quick facts
| Lead sponsor | University of Jordan |
|---|---|
| Phase | Phase 1 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 1 January 2023 |
| Primary completion | 30 January 2026 |
| Estimated completion | 30 January 2027 |
| Sites | 1 location across Jordan |
Drugs / interventions tested
- EV — full drug profile →
Conditions studied
- Vitiligo — all drugs for Vitiligo →
Sponsor
University of Jordan
Who can join
Adults 18 to 75, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Aim of the study: The primary endpoint of this work is to explore the safety of allogeneic extracellular secretomes "extracellular vesicles" (EV) derived from umbilical cord mesenchymal cells (HUCMSCs) when injected perilesional repeatedly in stable non-facial vitiligo. Methods: Adults with stable non-facial vitiligo for more than three months not exceeding 300 mm 2 were included in the study. A total of 13 patients of either gender, were given perilesional EV weekly for 3 weeks. Adverse events were regularly monitored for six months. The re-pigmentation was assessed at 3 and 6 months The non-injected areas are used as control for comparison of repigmentation. The injected skin area and the control areas were photographed at baseline, at the end of treatment, and at three, and six months.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Biological Nanotherapeutics Derived From Human Umbilical Cord Mesenchymal Stem Cells: Mechanisms and Translational Potential in Multisystem Therapies for Regeneration and Oncology.
Zhang R, Xu Z, Xu S, Li R, et al · · 2025 · cited 3× · PMID 41078403 · DOI 10.2147/ijn.s550390 -
The Multifaceted Role of Extracellular Vesicles in Alzheimer's Disease.
Da Conceicao ARR, Marinatto J, Pinheiro LS, Rody T, et al · · 2025 · cited 2× · PMID 40862476 · DOI 10.1111/jnc.70209 -
Tuning mechanical softness as a design principle in drug delivery: A biomechanical perspective.
Qi K, Zhang S, Bi X, Zhang Z, et al · · 2026 · cited 1× · PMID 41909730 · DOI 10.1016/j.apsb.2025.11.037 -
Vitiligo as a Failure of Immune Resolution and Tissue Regeneration: From Stress Signals to Targeted Immune Modulation.
Pupo Silvestrini AV, Lucas JM, de Barros Cardoso CR, Lopes Badra Bentley MV. · · 2026 · PMID 42105025 · DOI 10.1007/s12016-026-09165-3
Verify or expand the search:
- PubMed search for NCT06813027
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of EV
Trials testing the same drug.
- NCT07232602 — KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People · Phase 1, PHASE2 · recruiting
- NCT05845814 — A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Me · Phase 1, PHASE2 · active not recruiting
- NCT04815213 — The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans · Phase 1 · active not recruiting
Other recruiting trials for Vitiligo
Currently open trials in the same condition.
- NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo · recruiting
- NCT07267273 — Betamethasone Phonophoresis For Vitiligo · NA · recruiting
- NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients · active not recruiting
- NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo · NA · active not recruiting
- NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo · Phase 1 · recruiting
Other University of Jordan trials
Trials by the same sponsor.
- NCT07370545 — Impact of Presentation Sequence on Patient Tooth Shade Selection · NA · completed
- NCT07279285 — Sweet-Tasting Solution Versus Placebo to Reduce Pain During Local Anesthetic Injection in Children · NA · not yet recruiting
- NCT07310485 — Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausa · NA · enrolling by invitation
- NCT06977009 — Influence of Occlusal Reduction on Endodontic Postoperative Pain · NA · recruiting
- NCT07212413 — Effect of Snow-plow Technique on the Postoperative Pain Following Direct Composite Restoration · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06813027 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Jordan
- Last refreshed: 30 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06813027.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing